Recapping Agennix

Oncology play Agennix plans heavily dilutive rights offering to fund Phase III

Unless they participate in an upcoming rights issue slated to raise an amount almost equal to the company's market cap, existing shareholders in oncology play Agennix

Read the full 262 word article

How to gain access

Continue reading with a
two-week free trial.